26 November 2024
In the News
David Rosen on FDA GLP-1 Legal Battle – 'It's a precedent in this area'
Foley & Lardner LLP partner David Rosen described the legal battle between compounding pharmacies and the U.S. Food and Drug Administration over GLP-1 drugs in the BioSpace article, "Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability."
